143 related articles for article (PubMed ID: 11378562)
61. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
Van Oers MH; Hagenbeek A; Van Glabbeke M; Teodorovic I
Ann Hematol; 2002 Oct; 81(10):553-7. PubMed ID: 12424535
[No Abstract] [Full Text] [Related]
62. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
63. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.
Hirt C; Schüler F; Dölken G
Semin Cancer Biol; 2003 Jun; 13(3):223-31. PubMed ID: 12959353
[TBL] [Abstract][Full Text] [Related]
64. Diffuse aggressive lymphoma.
Fisher RI; Miller TP; O'Connor OA
Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
[TBL] [Abstract][Full Text] [Related]
65. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
66. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
67. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
68. Prolonging remission with rituximab maintenance therapy.
Hainsworth JD
Semin Oncol; 2004 Feb; 31(1 Suppl 2):17-21. PubMed ID: 15042530
[TBL] [Abstract][Full Text] [Related]
69. Rituximab in autologous stem cell transplantation for follicular lymphoma.
Schmitz N
Anticancer Drugs; 2001 Jun; 12 Suppl 2():S21-4. PubMed ID: 11508933
[TBL] [Abstract][Full Text] [Related]
70. [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab].
Kataoka T; Ishida Y; Kurokawa R; Takeshita S; Ohta K; Nishimura Y; Yokoyama M
Nihon Kokyuki Gakkai Zasshi; 2003 Dec; 41(12):899-904. PubMed ID: 14727553
[TBL] [Abstract][Full Text] [Related]
71. Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma.
Younes A; Hariharan K; Allen RS; Leigh BR
Clin Lymphoma; 2003 Mar; 3(4):257-9. PubMed ID: 12672278
[No Abstract] [Full Text] [Related]
72. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
73. Rituximab as maintenance therapy for patients with follicular lymphoma.
Vidal L; Gafter-Gvili A; Leibovici L; Shpilberg O
Cochrane Database Syst Rev; 2009 Apr; (2):CD006552. PubMed ID: 19370640
[TBL] [Abstract][Full Text] [Related]
74. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
Hainsworth JD; Litchy S; Burris HA; Scullin DC; Corso SW; Yardley DA; Morrissey L; Greco FA
J Clin Oncol; 2002 Oct; 20(20):4261-7. PubMed ID: 12377971
[TBL] [Abstract][Full Text] [Related]
75. Rituximab maintenance therapy: a step forward in follicular lymphoma.
van Oers MH
Haematologica; 2007 Jun; 92(6):826-33. PubMed ID: 17550856
[TBL] [Abstract][Full Text] [Related]
76. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab.
Pels H; Schulz H; Manzke O; Hom E; Thall A; Engert A
J Neurooncol; 2002 Sep; 59(3):213-6. PubMed ID: 12241117
[TBL] [Abstract][Full Text] [Related]
77. Patient benefits of maintenance immunotherapy.
Ghielmini M
Leuk Res; 2006 Mar; 30 Suppl 1():S22-6. PubMed ID: 16750675
[TBL] [Abstract][Full Text] [Related]
78. Principles of maintenance therapy.
Berinstein NL
Leuk Res; 2006 Mar; 30 Suppl 1():S3-10. PubMed ID: 16750676
[TBL] [Abstract][Full Text] [Related]
79. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature.
Freim Wahl SG; Folvik MR; Torp SH
Clin Neuropathol; 2007; 26(2):68-73. PubMed ID: 17416105
[TBL] [Abstract][Full Text] [Related]
80. Treatment of a patient with chronic renal failure with rituximab for a follicular lymphoma: safe and successful option of rituximab therapy.
Abdelkefi A; Mellouli F; Béjaoui M
Eur J Haematol; 2003 Aug; 71(2):128-9. PubMed ID: 12890153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
